Dark Horse Consulting Group Acquires BCVG To Expand Regenerative Medicine

KUALA LUMPUR, Jan 13 (Bernama) -- Dark Horse Consulting Group (DHCG), a strategic and operational biotherapeutics consulting firm, has acquired Bruder Consulting & Venture Group (BCVG), a strategic advisory firm with a global footprint in biotech and biopharma.

Following the acquisition, BCVG has been integrated into Dark Horse Consulting (DHC) as a dedicated department known as DHC Regenerative Medicine, according to the Group in a statement.

DHCG Founder and Chief Executive Officer (CEO), Anthony Davies said the addition of BCVG marked another milestone in DHCG’s ongoing strategic growth.

“BCVG’s deep experience in regenerative medicine enriches our collective expertise and accelerates our capacity to deliver comprehensive solutions to developers and investors, ultimately helping advance therapies further and faster for the benefit of patients worldwide,” he added.

Meanwhile, BCVG Founder and CEO, Scott P. Bruder said joining DHCG allowed the company to scale its expertise and expand support for client partners across all stages of the development process.

“Our expertise in regenerative medicine adds additional value and service offerings to the Group’s current clients,” said Bruder.

This acquisition strengthens DHCG’s patient-centred commitment to accelerating the development and commercialisation of biotherapeutics by building out an integrated ecosystem of consulting services.

BCVG’s global reach further extends DHCG’s capabilities in regenerative medicine, tissue repair, and biomaterials, following the Group’s recent strategic expansions.

As part of the transaction, BCVG was represented by Goodwin Procter LLP and Edgemont Partners, while DHCG was represented by Fenwick & West LLP.

-- BERNAMA